BioArctic AB Series B
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more
BioArctic AB Series B (0RV2) - Net Assets
Latest net assets as of December 2021: Skr788.68 Million SEK
Based on the latest financial reports, BioArctic AB Series B (0RV2) has net assets worth Skr788.68 Million SEK as of December 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr897.73 Million) and total liabilities (Skr109.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr788.68 Million |
| % of Total Assets | 87.85% |
| Annual Growth Rate | 5.52% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 29.64 |
BioArctic AB Series B - Net Assets Trend (2017–2021)
This chart illustrates how BioArctic AB Series B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioArctic AB Series B (2017–2021)
The table below shows the annual net assets of BioArctic AB Series B from 2017 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-12-31 | Skr788.68 Million | -13.07% |
| 2020-12-31 | Skr907.30 Million | -6.90% |
| 2019-12-31 | Skr974.50 Million | -4.25% |
| 2018-12-31 | Skr1.02 Billion | +59.99% |
| 2017-12-31 | Skr636.13 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioArctic AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 207.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2021)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr225.94 Million | 28.65% |
| Common Stock | Skr1.76 Million | 0.22% |
| Other Components | Skr560.98 Million | 71.13% |
| Total Equity | Skr788.68 Million | 100.00% |
BioArctic AB Series B Competitors by Market Cap
The table below lists competitors of BioArctic AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Adaro Minerals Indonesia Tbk PT
JK:ADMR
|
$734.43 Million |
|
S N Nuclearele
RO:SNN
|
$734.58 Million |
|
Pasifik Eurasia Lojistik Dis Ticaret A.S.
IS:PASEU
|
$734.61 Million |
|
Radius Recycling, Inc.
NASDAQ:RDUS
|
$734.62 Million |
|
CGN Mining Company Limited
PINK:CGNMF
|
$733.90 Million |
|
Baosheng
SHG:600973
|
$733.82 Million |
|
Técnicas Reunidas S.A
PINK:TNISF
|
$733.74 Million |
|
Amore Group
KO:002790
|
$733.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioArctic AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from 907,299,000 to 788,676,000, a change of -118,623,000 (-13.1%).
- Net loss of 119,790,000 reduced equity.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-119.79 Million | -15.19% |
| Other Changes | Skr1.17 Million | +0.15% |
| Total Change | Skr- | -13.07% |
Book Value vs Market Value Analysis
This analysis compares BioArctic AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently BioArctic AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -517.54%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.14x
- Recent ROE (-15.19%) is below the historical average (5.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 2.38% | 10.77% | 0.12x | 1.79x | Skr-48.46 Million |
| 2018 | 37.50% | 53.45% | 0.51x | 1.37x | Skr279.83 Million |
| 2019 | 9.08% | 31.40% | 0.24x | 1.21x | Skr-8.98 Million |
| 2020 | -7.55% | -109.90% | 0.06x | 1.16x | Skr-159.25 Million |
| 2021 | -15.19% | -517.54% | 0.03x | 1.14x | Skr-198.66 Million |
Industry Comparison
This section compares BioArctic AB Series B's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioArctic AB Series B (0RV2) | Skr788.68 Million | 2.38% | 0.14x | $734.10 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |